1-8 of 8
Brenda F. Kurland
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FDG PET and FES PET Predict PFS on Endocrine Therapy—Response

Brenda F. Kurland, Lanell M. Peterson, Hannah M. Linden, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 249–250.
https://doi.org/10.1158/1078-0432.CCR-17-2980
Published: 02 January 2018
View article titled, FDG PET and FES PET Predict PFS on Endocrine Therapy—Response
Open the PDF for FDG PET and FES PET Predict PFS on Endocrine Therapy—Response in another window
Journal Articles

FDG PET and FES PET Predict PFS on Endocrine Therapy—Response

Brenda F. Kurland, Hannah M. Linden, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (13): 3475.
https://doi.org/10.1158/1078-0432.CCR-17-0479
Published: 02 July 2017
View article titled, FDG PET and FES PET Predict PFS on Endocrine Therapy—Response
Open the PDF for FDG PET and FES PET Predict PFS on Endocrine Therapy—Response in another window
Journal Articles

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer

Brenda F. Kurland, Lanell M. Peterson, Jean H. Lee, Erin K. Schubert, Erin R. Currin, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff, Hannah M. Linden
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (2): 407–415.
https://doi.org/10.1158/1078-0432.CCR-16-0362
Published: 15 January 2017
View article titled, Estrogen Receptor Binding (<sup>18</sup>F-FES PET) and Glycolytic Activity (<sup>18</sup>F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER<sup>+</sup> Breast Cancer
Open the PDF for Estrogen Receptor Binding (<sup>18</sup>F-FES PET) and Glycolytic Activity (<sup>18</sup>F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer

Eve T. Rodler, Brenda F. Kurland, Melissa Griffin, Julie R. Gralow, Peggy Porter, Rosa F. Yeh, Vijayakrishna K. Gadi, Jamie Guenthoer, Jan H. Beumer, Larissa Korde, Sandra Strychor, Brian F. Kiesel, Hannah M. Linden, John A. Thompson, Elizabeth Swisher, Xiaoyu Chai, Stacie Shepherd, Vincent Giranda, Jennifer M. Specht
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2855–2864.
https://doi.org/10.1158/1078-0432.CCR-15-2137
Published: 14 June 2016
View article titled, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer
Open the PDF for Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or <em>BRCA</em> Mutation–Associated Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

Peilu Wang, Amir Bahreini, Rekha Gyanchandani, Peter C. Lucas, Ryan J. Hartmaier, Rebecca J. Watters, Amruth R. Jonnalagadda, Humberto E. Trejo Bittar, Aaron Berg, Ronald L. Hamilton, Brenda F. Kurland, Kurt R. Weiss, Aju Mathew, Jose Pablo Leone, Nancy E. Davidson, Marina N. Nikiforova, Adam M. Brufsky, Tadeu F. Ambros, Andrew M. Stern, Shannon L. Puhalla, Adrian V. Lee, Steffi Oesterreich
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (5): 1130–1137.
https://doi.org/10.1158/1078-0432.CCR-15-1534
Published: 29 February 2016
View article titled, Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Open the PDF for Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer

Hannah M. Linden, Brenda F. Kurland, Lanell M. Peterson, Erin K. Schubert, Julie R. Gralow, Jennifer M. Specht, Georgiana K. Ellis, Thomas J. Lawton, Robert B. Livingston, Philip H. Petra, Jeanne M. Link, Kenneth A. Krohn, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (14): 4799–4805.
https://doi.org/10.1158/1078-0432.CCR-10-3321
Published: 17 July 2011
View article titled, Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer
Open the PDF for Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake

Lisa K. Dunnwald, Robert K. Doot, Jennifer M. Specht, Julie R. Gralow, Georgiana K. Ellis, Robert B. Livingston, Hannah M. Linden, Vijayakrishna K. Gadi, Brenda F. Kurland, Erin K. Schubert, Mark Muzi, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2400–2409.
https://doi.org/10.1158/1078-0432.CCR-10-2649
Published: 14 April 2011
View article titled, PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake
Open the PDF for PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake in another window
Journal Articles

Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer

Jennifer M. Specht, Brenda F. Kurland, Susan K. Montgomery, Lisa K. Dunnwald, Robert K. Doot, Julie R. Gralow, Georgina K. Ellis, Hannah M. Linden, Robert B. Livingston, Kimberly H. Allison, Erin K. Schubert, David A. Mankoff
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2803–2810.
https://doi.org/10.1158/1078-0432.CCR-10-0026
Published: 13 May 2010
View article titled, Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer
Open the PDF for Tumor Metabolism and Blood Flow as Assessed by Positron Emission Tomography Varies by Tumor Subtype in Locally Advanced Breast Cancer in another window